Top > Search of International Patents > RADIATION THERAPY AGENT

RADIATION THERAPY AGENT

Foreign code F120006517
File No. S2010-0590-C0
Posted date May 8, 2012
Country WIPO
International application number 2011JP053348
International publication number WO 2011102407
Date of international filing Feb 17, 2011
Date of international publication Aug 25, 2011
Priority data
  • P2010-032055 (Feb 17, 2010) JP
Title RADIATION THERAPY AGENT
Abstract Disclosed is a radiation therapy agent which contains compound particles which, formed by molecules specifically recognizing a target compound binding to substrate particles containing titanium peroxide, generate reactive oxygen species when exposed to radiation. Further, because the disclosed radiation therapy agent contains molecules specifically recognizing a target compound, said radiation therapy agent has the property of accumulating around the target compound. The disclosed radiation therapy agent is capable of enhancing the effects of radiation therapy, and is capable of decreasing adverse effects on the living organism by efficiently attacking the target compound.
Outline of related art and contending technology BACKGROUND ART
1 As one of a cancer treatment, radiation treatment is performed. X-ray or γ-ray radiation treatment may be by irradiation or killing or suppressing growth of cancer cells to therapy. Topical treatment and radiation therapy generally, systemic invasive to small, medical relaxation to reduce the burden to the patient as well and is considered to be an important means.
Radiation treatments, from outside the external irradiation method is a test-pattern is illuminated and a lesion, X-ray, γ ray, electron beam, particle beam and the like are used. External beam radiation method, a sufficient amount of radiation that reaches the tumor, radiation on the tumor and surrounding normal tissues is not so much as featured, consider the irradiation direction of the radiation required. Radiation, irradiation from one direction while in other cases, a large number of irradiated from a direction in some cases. When treating a tumor that is deep in the body, and high-level radiation needs to be irradiated, the problem of side effects.
Radiation therapy side effects to normal tissues, in a region irradiated with basically occurs. Reactions may include normal tissue, mucosa occurs during irradiation, failure of an epithelial cells, 6 months treatment is to be terminated after the lapse of several years - generated from stromal cells, vascular endothelial cell dysfunction and the like. Side effects of radiation therapy, irradiation dose, the irradiation site, the patient's age, varied depending on the general condition. While reducing the side effects, can effectively kill cancer cells such as radiation therapy is desired.
In recent years, the photocatalytic titanium dioxide and is used in various fields, has attracted attention. To act as a photocatalyst, titanium dioxide is irradiated with light in the wavelength shorter than 380 nm by the generated active oxygen species based on the oxidizing strength of the. Photocatalytic activity, the decomposing treatment of hazardous chemicals such as environmental hormones, sterilizing harmful microorganisms, and antimicrobial used, further cancer therapy has been applied research (non-patent document 1-4).
Titanium dioxide modified with a hydrophilic polymer, further capable of specific binding of target molecules immobilized with a titanium dioxide composite, such as cancer cells with a photocatalyst has the effect of decomposing by the action disclosed (patent document 1). Such titanium dioxide composite, exerts an action of the photocatalyst by irradiation with ultraviolet light.
And the ultrasonic wave is applied to titanium dioxide, to produce a high concentration of hydroxyl radicals have been identified (titanium dioxide/ultrasonic catalyst method). Polyacrylic acid coated with titanium dioxide, titanium dioxide pre/S2 hepatocytes recognition protein bound and the disclosure of which is the compound particles, such composite particle comprises, liver cancer cells can be specifically targeted, to kill cancer cells by irradiation of the ultrasonic wave, exerts an action of causing damage (patent document 2).
The use of radiation therapy to the photocatalytic activity although the desired, and the like have the irradiation dose, so that it can withstand practical use photocatalytic material is not yet been found.
Scope of claims (In Japanese)請求の範囲 [請求項1]
過酸化チタンを含む基体粒子に、標的物を特異的に認識する分子が結合してなる、放射線照射により標的物に障害を与える活性酸素を発生する複合体粒子を含む、放射線治療剤。

[請求項2]
前記活性酸素がヒドロキシラジカルである請求項1に記載の放射線治療剤。

[請求項3]
前記基体粒子の過酸化チタンが主として基体粒子表面に分布していることを特徴とする請求項1または2に記載の放射線治療剤。

[請求項4]
基体粒子が、さらに二酸化チタンを含むものである、請求項1~3のいずれか1に記載の放射線治療剤。

[請求項5]
基体粒子の平均分散粒径が、1nm以上200nm以下である、請求項1~4のいずれか1に記載の放射線治療剤。

[請求項6]
標的物を特異的に認識する分子が、抗体である、請求項1~5のいずれか1に記載の放射線治療剤。

[請求項7]
前記複合体粒子が、基体粒子の表面の少なくとも一部が高分子被膜により被覆されており、標的物を特異的に認識する分子が、当該高分子被膜を介して基体粒子に結合してなる、請求項1~6のいずれか1に記載の放射線治療剤。

[請求項8]
放射線がX線である、請求項1~7のいずれか1に記載の放射線治療剤。

[請求項9]
水、pH緩衝液、輸液、又は生理食塩水の中に複合体粒子が自主分散しており、当該複合体粒子が、過酸化チタンを含む基体粒子に、標的物を特異的に認識する分子が結合してなる、放射線照射により標的物に障害を与える活性酸素を発生する複合体粒子である、分散液。

[請求項10]
前記複合体粒子の表面電位が+20mV以上である、請求項9に記載の分散液。

[請求項11]
請求項9または10の分散液である、放射線治療剤。

[請求項12]
標的物を特異的に認識する分子が、腫瘍細胞を特異的に認識し得る抗体である、請求項1~8および11のいずれか1に記載の放射線治療剤を含む、抗腫瘍剤。

  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY
  • Inventor
  • OGINO, Chiaki
  • TANAKA, Tsutomu
  • SASAKI, Ryohei
  • KONDO, Akihiko
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close